National Center for Tumor Diseases (NCT) Heidelberg
Dr. Irfan A. Bhatti currently serves as a Clinical Investigator at the National Center for Tumor Diseases (NCT) Heidelberg, specializing in screening, recruiting, and treating patients in precision oncology trials since February 2019. In addition to this role, Dr. Bhatti has experience as a Clinical Fellow in Internal Medicine, Hematology, and Medical Oncology. Since July 2010, Dr. Bhatti has also been a Consultant at Aumapharma and previously held the position of Medical Consultant at Qrumpharma Inc. from February 2015 to December 2020. Dr. Bhatti's academic credentials include a Master of Science in Medical Biometry and Biostatistics from Heidelberg University and a Doctor of Medicine degree from Justus Liebig University Giessen, complemented by advanced studies at Goethe University Frankfurt and The Philipp University of Marburg.
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.